Browse NOS2

Summary
SymbolNOS2
Namenitric oxide synthase 2, inducible
Aliases HEP-NOS; NOS2A; nitric oxide synthase 2A (inducible, hepatocytes); NOSA; NOS type II; NOS, type II; hepatocy ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00667 FAD binding domain
PF00258 Flavodoxin
PF00175 Oxidoreductase NAD-binding domain
PF02898 Nitric oxide synthase
Function

Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body (PubMed:7531687, PubMed:7544004). In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2 (By similarity). As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM (PubMed:25417112). Involved in inflammation, enhances the synthesis of proinflammatory mediators such as IL6 and IL8 (PubMed:19688109).

> Gene Ontology
 
Biological Process GO:0001666 response to hypoxia
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001912 positive regulation of leukocyte mediated cytotoxicity
GO:0002227 innate immune response in mucosa
GO:0002237 response to molecule of bacterial origin
GO:0002251 organ or tissue specific immune response
GO:0002385 mucosal immune response
GO:0002532 production of molecular mediator involved in inflammatory response
GO:0002534 cytokine production involved in inflammatory response
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006091 generation of precursor metabolites and energy
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006182 cGMP biosynthetic process
GO:0006520 cellular amino acid metabolic process
GO:0006525 arginine metabolic process
GO:0006527 arginine catabolic process
GO:0006801 superoxide metabolic process
GO:0006809 nitric oxide biosynthetic process
GO:0006820 anion transport
GO:0006869 lipid transport
GO:0007263 nitric oxide mediated signal transduction
GO:0007623 circadian rhythm
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0009063 cellular amino acid catabolic process
GO:0009064 glutamine family amino acid metabolic process
GO:0009065 glutamine family amino acid catabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0009306 protein secretion
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0010876 lipid localization
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015732 prostaglandin transport
GO:0015833 peptide transport
GO:0015908 fatty acid transport
GO:0015980 energy derivation by oxidation of organic compounds
GO:0016054 organic acid catabolic process
GO:0017014 protein nitrosylation
GO:0018119 peptidyl-cysteine S-nitrosylation
GO:0018198 peptidyl-cysteine modification
GO:0019932 second-messenger-mediated signaling
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030823 regulation of cGMP metabolic process
GO:0030825 positive regulation of cGMP metabolic process
GO:0030826 regulation of cGMP biosynthetic process
GO:0030828 positive regulation of cGMP biosynthetic process
GO:0031279 regulation of cyclase activity
GO:0031281 positive regulation of cyclase activity
GO:0031282 regulation of guanylate cyclase activity
GO:0031284 positive regulation of guanylate cyclase activity
GO:0031341 regulation of cell killing
GO:0031343 positive regulation of cell killing
GO:0031640 killing of cells of other organism
GO:0032309 icosanoid secretion
GO:0032310 prostaglandin secretion
GO:0032496 response to lipopolysaccharide
GO:0032635 interleukin-6 production
GO:0032637 interleukin-8 production
GO:0034341 response to interferon-gamma
GO:0035150 regulation of tube size
GO:0035690 cellular response to drug
GO:0035821 modification of morphology or physiology of other organism
GO:0036293 response to decreased oxygen levels
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0042311 vasodilation
GO:0042312 regulation of vasodilation
GO:0042493 response to drug
GO:0042742 defense response to bacterium
GO:0042886 amide transport
GO:0043457 regulation of cellular respiration
GO:0043467 regulation of generation of precursor metabolites and energy
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0044057 regulation of system process
GO:0044282 small molecule catabolic process
GO:0044364 disruption of cells of other organism
GO:0045333 cellular respiration
GO:0045454 cell redox homeostasis
GO:0045776 negative regulation of blood pressure
GO:0045909 positive regulation of vasodilation
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046068 cGMP metabolic process
GO:0046209 nitric oxide metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046395 carboxylic acid catabolic process
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046942 carboxylic acid transport
GO:0048511 rhythmic process
GO:0050663 cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050727 regulation of inflammatory response
GO:0050796 regulation of insulin secretion
GO:0050829 defense response to Gram-negative bacterium
GO:0050880 regulation of blood vessel size
GO:0051339 regulation of lyase activity
GO:0051349 positive regulation of lyase activity
GO:0051709 regulation of killing of cells of other organism
GO:0051712 positive regulation of killing of cells of other organism
GO:0052652 cyclic purine nucleotide metabolic process
GO:0070482 response to oxygen levels
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071346 cellular response to interferon-gamma
GO:0071396 cellular response to lipid
GO:0071715 icosanoid transport
GO:0072522 purine-containing compound biosynthetic process
GO:0072593 reactive oxygen species metabolic process
GO:0072604 interleukin-6 secretion
GO:0072606 interleukin-8 secretion
GO:0090066 regulation of anatomical structure size
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0098542 defense response to other organism
GO:1900015 regulation of cytokine production involved in inflammatory response
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901565 organonitrogen compound catabolic process
GO:1901605 alpha-amino acid metabolic process
GO:1901606 alpha-amino acid catabolic process
GO:1903409 reactive oxygen species biosynthetic process
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:2001057 reactive nitrogen species metabolic process
Molecular Function GO:0004497 monooxygenase activity
GO:0004517 nitric-oxide synthase activity
GO:0005516 calmodulin binding
GO:0010181 FMN binding
GO:0016597 amino acid binding
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016709 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen
GO:0020037 heme binding
GO:0031406 carboxylic acid binding
GO:0034617 tetrahydrobiopterin binding
GO:0034618 arginine binding
GO:0043168 anion binding
GO:0046906 tetrapyrrole binding
GO:0048037 cofactor binding
GO:0050660 flavin adenine dinucleotide binding
GO:0050661 NADP binding
GO:0050662 coenzyme binding
Cellular Component GO:0005777 peroxisome
GO:0005938 cell cortex
GO:0030863 cortical cytoskeleton
GO:0042579 microbody
GO:0044448 cell cortex part
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04146 Peroxisome
hsa00330 Arginine and proline metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-392154: Nitric oxide stimulates guanylate cyclase
R-HSA-418346: Platelet homeostasis
R-HSA-1222556: ROS, RNS production in phagocytes
R-HSA-449147: Signaling by Interleukins
Summary
SymbolNOS2
Namenitric oxide synthase 2, inducible
Aliases HEP-NOS; NOS2A; nitric oxide synthase 2A (inducible, hepatocytes); NOSA; NOS type II; NOS, type II; hepatocy ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NOS2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between NOS2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22529296MelanomaInhibit immunity (T cell function)These data suggest a critical role for tumor-expressed iNOS in the recruitment and induction of functional MDSC by modulation of tumor VEGF secretion and upregulation of STAT3 and ROS in MDSC.
22474024Colon CarcinomaInhibit immunity (T cell function)Experiments using small interfering RNA and a chemical inhibitor of FKBP51 revealed that FKBP51 contributes to the regulation of the suppressive function of MDSCs by increasing inducible NO synthase, arginase-1, and reactive oxygen species levels and enhancing NF-κB activity.
27622331Colorectal CarcinomaPromote immunity (T cell function)These myeloid cells are phenotypically similar to inducible nitric oxide synthase (NOS2)- and tumor necrosis factor (TNF)-producing dendritic cells (DC), or Tip-DCs. Tumor elimination via NOS2 required the CD40-CD40L pathway. We also uncovered a strong correlation between survival of colorectal cancer patients and NOS2, CD40, and TNF expression in their tumors.
19739080Ovarian CarcinomaInhibit immunity (T cell function)The immunosuppression of CD4(+) T cells is independent of direct contact with the Hospicells and is mainly due to nitric oxide produced by the inducible nitric oxide synthase and to products of the tryptophan degradation by indoleamine 2,3-dioxygenase.
17785863GliomaInhibit immunityIn this study, we show that the inducible NO synthase (iNOS)-specific inhibitor mercaptoethylguanidine (MEG) superiorly enhanced lymphocyte reactivity after polyclonal stimulation compared with the iNOS-specific inhibitor L-NIL and the unspecific NO synthase inhibitor L-NAME. Both iNOS inhibitors increased the number and proliferation of T cells but not of B cells.
29634348hepatocellular carcinomaInhibit immunityIt is becoming increasingly evident that nitric oxide synthase 2 (NOS2)-mediated NO/reactive nitrogen oxide species (RNS) are heavily involved in cancer progression and metastasis in different types of tumor.
23975435B16 Malignant MelanomaInhibit immunityInterestingly, this tumor-promoting effect by p53-deficient MSCs was not observed in non-obese diabetic/severe combined immunodeficiency mice, indicating the immune response has a critical role. Indeed, in the presence of inflammatory cytokines, p53-deficient MSCs expressed more inducible nitric oxide synthase (iNOS) and exhibited greater immunosuppressive capacity. Importantly, tumor promotion by p53-deficient MSCs was abolished by administration of S-methylisothiourea, an iNOS inhibitor.
29124314MelanomaInhibit immunityFurthermore, Foxp3 vaccination resulted in a significant reduction of arginase-1(Arg-1)-induced nitric oxide synthase (iNOS), reactive oxygen species (ROS) and suppressed MDSC activity. Moreover, this concurrent depletion restored production of inflammatory cytokine IFN-γ and enhanced tumor-specific CTL response, which subsequently resulted in the reduction of tumor growth and the improved survival rate of vaccinated mice.
22075702Melanoma; Breast CarcinomaPromote immunityTumor cell killing mediated by Th-1-activated killer DCs was dependent on inducible NO synthase expression and NO production.
17617571Colon CarcinomaPromote immunityBMDC-mediated tumor cell killing requires cell-cell contact and depends on NO production, but not on perforin/granzyme or on death receptors. Thus, intratumoral LPS injections induce an increase of inducible NO synthase expression in tumor-infiltrating DCs associated with a significant arrest of tumor growth.
Summary
SymbolNOS2
Namenitric oxide synthase 2, inducible
Aliases HEP-NOS; NOS2A; nitric oxide synthase 2A (inducible, hepatocytes); NOSA; NOS type II; NOS, type II; hepatocy ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NOS2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNOS2
Namenitric oxide synthase 2, inducible
Aliases HEP-NOS; NOS2A; nitric oxide synthase 2A (inducible, hepatocytes); NOSA; NOS type II; NOS, type II; hepatocy ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NOS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.160.476
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4660.33
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0570.87
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3490.563
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.330.794
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3780.794
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3420.527
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3580.644
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1170.892
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7910.183
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7190.0207
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3550.199
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NOS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.16.84.30.443
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.18.52.60.702
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.418.2-2.81
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNOS2
Namenitric oxide synthase 2, inducible
Aliases HEP-NOS; NOS2A; nitric oxide synthase 2A (inducible, hepatocytes); NOSA; NOS type II; NOS, type II; hepatocy ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NOS2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNOS2
Namenitric oxide synthase 2, inducible
Aliases HEP-NOS; NOS2A; nitric oxide synthase 2A (inducible, hepatocytes); NOSA; NOS type II; NOS, type II; hepatocy ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NOS2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NOS2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNOS2
Namenitric oxide synthase 2, inducible
Aliases HEP-NOS; NOS2A; nitric oxide synthase 2A (inducible, hepatocytes); NOSA; NOS type II; NOS, type II; hepatocy ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NOS2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNOS2
Namenitric oxide synthase 2, inducible
Aliases HEP-NOS; NOS2A; nitric oxide synthase 2A (inducible, hepatocytes); NOSA; NOS type II; NOS, type II; hepatocy ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NOS2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNOS2
Namenitric oxide synthase 2, inducible
Aliases HEP-NOS; NOS2A; nitric oxide synthase 2A (inducible, hepatocytes); NOSA; NOS type II; NOS, type II; hepatocy ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NOS2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNOS2
Namenitric oxide synthase 2, inducible
Aliases HEP-NOS; NOS2A; nitric oxide synthase 2A (inducible, hepatocytes); NOSA; NOS type II; NOS, type II; hepatocy ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NOS2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NOS2.
ID Name Drug Type Targets #Targets
DB00125L-ArginineSmall MoleculeARG2, ASL, ASS1, AZIN2, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A49
DB00155L-CitrullineSmall MoleculeASS1, DDAH1, DDAH2, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PA ......12
DB01110MiconazoleSmall MoleculeKCNH2, KCNH6, KCNH7, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1 ......15
DB01234DexamethasoneSmall MoleculeANXA1, NOS2, NR0B1, NR1I2, NR3C15
DB01686N,N-dimethylarginineSmall MoleculeNOS2, NOS32
DB018354r-Fluoro-N6-Ethanimidoyl-L-LysineSmall MoleculeNOS21
DB019973-Bromo-7-NitroindazoleSmall MoleculeNOS1, NOS2, NOS33
DB02044N-(3-(Aminomethyl)Benzyl)AcetamidineSmall MoleculeNOS1, NOS2, NOS33
DB022077-NitroindazoleSmall MoleculeNOS2, NOS32
DB02234S-EthylisothioureaSmall MoleculeNOS2, NOS32
DB02462ThiocoumarinSmall MoleculeNOS21
DB02644N-Omega-Propyl-L-ArginineSmall MoleculeNOS1, NOS22
DB031006-NitroindazoleSmall MoleculeNOS2, NOS32
DB03144N-Omega-Hydroxy-L-ArginineSmall MoleculeARG1, NOS1, NOS2, NOS34
DB03366ImidazoleSmall MoleculeAK2, CYCS, DMC1, GPHN, LTA4H, MB, MYO1E, NOS2, PIM19
DB03449N-(4-(2-((3-Chlorophenylmethyl)Amino)Ethyl)Phenyl)-2-ThiophecarboxamidineSmall MoleculeNOS1, NOS22
DB03953L-ThiocitrullineSmall MoleculeNOS21
DB04400L-erythro-7,8-dihydrobiopterinSmall MoleculeNOS2, PAH, PCBD1, TH4
DB045345-NitroindazoleSmall MoleculeNOS2, NOS32
DB05214KD7040Small MoleculeNOS21
DB05252Fenoxaprop-ethylSmall MoleculeNOS21
DB05383PimagedineSmall MoleculeAKR1B1, NOS2, TIMP33
DB068795-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILESmall MoleculeNOS21
DB06916N-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-1-[2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDIN-4-YL]-D-PROLINAMIDESmall MoleculeNOS21
DB070024-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrileSmall MoleculeNOS21
DB07003(2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amineSmall MoleculeNOS21
DB07007(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amineSmall MoleculeNOS21
DB070084-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PYRIMIDINESmall MoleculeNOS21
DB07011(3S)-1-(1,3-BENZODIOXOL-5-YLMETHYL)-3-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PIPERIDINESmall MoleculeNOS21
DB070294-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]-6-METHYLPYRIMIDINESmall MoleculeNOS21
DB07306ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATESmall MoleculeNOS21
DB07318N-[2-(4-AMINO-5,8-DIFLUORO-1,2-DIHYDROQUINAZOLIN-2-YL)ETHYL]-3-FURAMIDESmall MoleculeNOS21
DB07388ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATESmall MoleculeNOS2, NOS32
DB07389N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDESmall MoleculeNOS21
DB074051-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINESmall MoleculeNOS21
DB082144-(1H-IMIDAZOL-1-YL)PHENOLSmall MoleculeNOS21
DB087501-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINESmall MoleculeNOS21
DB08814TriflusalSmall MoleculeNFKB1, NOS2, PDE10A, PTGS14
DB09237LevamlodipineSmall MoleculeCACNA1C, NOS2, NOS33